There is no doubt that AI represents an opportunity to transform the drug development and commercialization process and value that ...

The life sciences industry has experienced breakthroughs on multiple fronts over the past few years and 2019 was no different. ...

Increased globalization and the growing complexities around innovative, next-generation therapies has forced biopharmaceutical leaders to reexamine their clinical supply chain ...

In the age of precision and personalized medicine, life science companies can develop treatments designed to target almost any patient’s ...

On July 31, 2019, the White House announced an iterative healthcare plan that would allow the importation of Canadian drugs ...

Since the antihistamine brompheniramine maleate (i.e., Dimetapp today) made the switch from Rx to OTC in 1976, 115 more products ...

In March, FDA commissioner Scott Gottlieb announced his resignation, which became effective last Friday, April 5th. Highly regarded by life ...

Clinical trials have long been viewed as complicated and high-volume endeavors, involving the widespread recruitment of patients, supply chain planning ...

Over half of US states have proposed new drug pricing laws and transparency legislation in the past two to three ...

As the U.S. continues to face the government shutdown in 2019, the longest in history, the lack of funding for ...

The 2019 pharmaceutical trends build off an exciting 2018 in pharma with new developments in artificial intelligence, R&D, personalized medicine, ...

“The right dose of the right medicine delivered to the right patient at the right time…and at the right cost”.  ...